BRAF and thyroid cancer: It has been shown that MEK inhibition increased invasion of metastatic melanoma cell lines, but reduced invasion of non-metastatic cell lines 43; BRAF inhibitor-resistant thyroid cancer cell line 8505C, but not BRAF inhibitor-sensitive BCPAP cells presented upregulated EMT following BRAF inhibitor PLX4032 treatment 51.